<DOC>
	<DOCNO>NCT00290680</DOCNO>
	<brief_summary>RATIONALE : Bortezomib celecoxib may stop growth tumor cell block enzymes need cell growth . Giving bortezomib together celecoxib may kill tumor cell . PURPOSE : This phase I trial study side effect best dose bortezomib celecoxib treat patient advance solid tumor .</brief_summary>
	<brief_title>Bortezomib Celecoxib Treating Patients With Advanced Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine maximum tolerate dose ( MTD ) bortezomib celecoxib patient advance solid tumor . Secondary - Determine overall pattern toxicity associate combination , include emergence cumulative toxicity , multiple course regimen . - Describe response rate duration response disease stability therapy subset patient measurable disease . - Assess change plasma/serum sphingosine-1-phosphate , ceramide , marker apoptotic pathway therapy . OUTLINE : This dose-escalation study . Patients receive bortezomib IV day 1 , 4 , 8 , 11 day 1 , 8 , 15 , 22 , 29 oral celecoxib twice daily day 1-21 1-42 . Courses repeat every 21 42 day absence disease progression unacceptable toxicity . Patients evaluate every 2 course . Patients achieve complete response ( CR ) receive 2 additional course therapy beyond CR . Cohorts 3-6 patient receive escalate dos bortezomib celecoxib maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 6 patient experience dose-limiting toxicity . After completion study treatment , patient follow every 3 month . PROJECTED ACCRUAL : A total 36 patient accrue study .</detailed_description>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Celecoxib</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologic cytologic diagnosis malignant neoplasm ( solid tumor ) arise primary site exception bone marrow lymphoid tissue Recurrent progressive disease chemotherapy radiotherapy Chemotherapy radiotherapynaive disease allow patient candidate standard treatment either due comorbidities lack willingness undergo standard treatment Measurable disease PATIENT CHARACTERISTICS : ECOG performance status 02 Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Creatinine ≤ 2.0 mg/dL OR creatinine clearance ≥ 30 mL/min Bilirubin ≤ 2 mg/dL Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No active concurrent invasive malignancy No peripheral neuropathy ≥ grade 2 within past 14 day No hypersensitivity bortezomib , boron , mannitol , cyclooxygenase ( COX2 ) inhibitor , sulfa drug , nonsteroidal antiinflammatory drug ( NSAIDs ) No active gastrointestinal ( GI ) ulcer OR history GI bleeding result prior therapy NSAIDs PRIOR CONCURRENT THERAPY : At least 2 week since completion prior radiotherapy No prior bortezomib No concurrent investigational agent No concurrent chemotherapy , radiotherapy , anticancer surgery No concurrent immuneenhancing therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>